Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Global X Robo Global Robotics & Automation ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Global X Robo Global Robotics & Automation ETF trades at $76.01 (market cap $2.02B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Global X Robo Global Robotics & Automation ETF for 38 Days on average.
| DYN | ROBO | |
|---|---|---|
Market Cap | $2.86B | $2.02B |
Volume | 3,341,579 | 103,334 |
Sector | Health | Sector/Thematic |
52-Week High | $26.78 | $90.34 |
52-Week Low | $14.60 | $63.04 |
Typical Hold Time | 0 Days | 38 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.85, down 0.22% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure. The robotics ETF faces mixed sentiment amid AI-driven sector growth but lacks current fundamental data for valuation metrics. Recent news highlights robotics adoption expanding beyond automotive into manufacturing, healthcare, and military applications, though earnings visibility remains limited for underlying holdings.
The outlook for ROBO hinges on broader AI and robotics adoption trends, with potential from labor shortages and military demand, but risks include valuation concerns in tech and cyclical exposure. Investors should monitor earnings from constituent companies for fundamental validation of growth narratives amid neutral oscillator signals and bearish technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
